



Carisma Therapeutics to Participate in 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

PHILADELPHIA, Jan. 5, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and Chief Executive Officer of Carisma, will present at the [40th Annual J.P. Morgan Healthcare Conference](#). The presentation will take place virtually on January 12, 2022, at 7:30 am ET, and will be accessible to registered conference attendees.

About Carisma Therapeutics

Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA.

For more information, please visit www.carismatx.com

Carisma Media Contact:

Christina Khoury-Folkens
(929) 299-5962
ckhoury@realchemistry.com

SOURCE Carisma Therapeutics Inc.